Importantly, while loss of USP22 expression resulted in increased tumor growth and aggressiveness, activation of the mTOR pathway resulted in a synthetic vulnerability of USP22-deficient colorectal cancer cells to mTOR inhibitor treatment. This evidence concerns the gene USP22 and colorectal cancer.